Codiak Biosciences Stock
Biotechnology
Sign up today and learn more about Codiak Biosciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Codiak Biosciences Stock
Codiak Biosciences is developing exosomes, natural vesicles that mediate inter-cellular communication, as both a powerful therapeutic modality and an advanced diagnostic system. Codiak is building a world-class team and has generated and acquired foundational intellectual property that will allow it to capitalize on the unique potential of exosome biology.
Investors
Alaska Permanent Fund
Alexandria Venture Investments
ARCH Venture Partners
Grail, Prime Medicine, Aledade, Codiak Biosciences, Mindstrong, Metacrine, Beam Therapeutics
Boxer Capital
Casdin Capital
23andMe, Komodo Health, Genapsys, ORIC Pharmaceuticals, Codiak Biosciences, Vineti
EcoR1 Capital
Flagship Pioneering
Tessera Therapeutics, Indigo, Codiak Biosciences, Rubius Therapeutics, Cygnal Therapeutics
Qatar Investment Authority
Flipkart, SoFi, Eat Just, Thumbtack, impact.com, D2iQ, Codiak Biosciences, Checkout
Sirona Capital
Yukon Partners
Funding History
| November 2015 | $33.2M |
|---|---|
| November 2015 | $64.2M |
| November 2017 | $76.5M |
Management
Chief Executive Officer
Doug Williams
Chief Business Officer
Richard Brudnick
Chief Financial Officer
Linda C. Bain
Scientific Co-Founder
Raghu Kalluri
Scientific Co-Founder
Eric Lander
Chief Scientist
Jan Lötvall
Press
BusinessWire - Nov, 8 2019
Codiak Presents New Preclinical Data for First-in-Class Exosome Therapeutic Candidates, exoIL-12 and exoSTING, Demonstrating Potent Anti-Tumor ActivityBioSpace - May, 1 2019
Codiak Biosciences Lines up for $86 Million IPOexomes - Apr, 30 2019
Exosomes Head to Wall Street As Codiak Biosciences Lines Up IPOPR Newswire (press release) - Jun, 4 2018
Codiak BioSciences Names Richard Brudnick Chief Business Officer and Head of StrategyBusiness Wire (press release) - Dec, 21 2017
Stem Cell Exosomes Market Report 2017: Identify Opportunities for Exosome Product Development - Research and ...PR Newswire (press release) - Nov, 29 2017
Codiak BioSciences Closes $76.5 Million Series C FinancingEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
